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Global burden of Clostridium difficile infections: 
a systematic review and meta-analysis
Background Clostridium difficile is a leading cause of morbidity and mor-
tality in several countries. However, there are limited evidence character-
izing its role as a global public health problem. We conducted a system-
atic review to provide a comprehensive overview of C. difficile infections 
(CDI) rates.
Methods Seven databases were searched (January 2016) to identify stud-
ies and surveillance reports published between 2005 and 2015 reporting 
CDI incidence rates. CDI incidence rates for health care facility-associated 
(HCF), hospital onset-health care facility-associated, medical or general 
intensive care unit (ICU), internal medicine (IM), long-term care facility 
(LTCF), and community-associated (CA) were extracted and standardized. 
Meta-analysis was conducted using a random effects model.
Results 229 publications, with data from 41 countries, were included. 
The overall rate of HCF-CDI was 2.24 (95% confidence interval CI = 1.66-
3.03) per 1000 admissions/y and 3.54 (95%CI = 3.19-3.92) per 10 000 pa-
tient-days/y. Estimated rates for CDI with onset in ICU or IM wards were 
11.08 (95%CI = 7.19-17.08) and 10.80 (95%CI = 3.15-37.06) per 1000 ad-
mission/y, respectively. Rates for CA-CDI were lower: 0.55 (95%CI = 0.13-
2.37) per 1000 admissions/y. CDI rates were generally higher in North 
America and among the elderly but similar rates were identified in other 
regions and age groups.
Conclusions Our review highlights the widespread burden of disease of 
C. difficile, evidence gaps, and the need for sustainable surveillance of CDI 
in the health care setting and the community.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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health
global
Clostridium difficile is a leading cause of health care-associated infections (HAIs) 
and an important public health threat. C. difficile has been associated with sub-
stantial morbidity and mortality worldwide and among individuals of all ages 
beyond the traditionally recognized at-risk groups (eg, elderly, hospitalized pa-
tients, or those under antimicrobial therapy) [1]. In the United States, C. dif-
ficile caused an estimated half a million infections and 29 000 deaths in 2012 
[2]. Almost two thirds of these were associated with inpatient care, and more 
than 80% of these deaths occurred in those 65 years and over [2]. Challenges 
remain to control incidence of C. difficile infections (CDI) rates in other world 
regions such as Europe [3-5] and Asia [6]. It is estimated that approximately 
40 000 cases among inpatients are potentially underdiagnosed each year in Eu-
rope [5]. Furthermore, recurrence of CDI is estimated to occur among a con-
siderable percentage of cases (approximately 20%-30%) [7]. Though the global 
health care costs associated with CDI are not known, these are likely to be sub-
stantial with estimates suggesting attributable costs of US$ 5.4-6.3 billion per 
year in the United States [8].
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Considering the evolving epidemiology of C. difficile morbidity and mortality, global challenges regarding 
antibiotic stewardship and limited alternative preventative options for CDI, it is important to assess its 
burden to inform public health action. The emergence of hyper virulent strain PCR ribotype 027/NAP1, 
significant increases in incidence of hospitalizations associated with C. difficile by the mid-2000s, and out-
breaks of CDI in hospitals globally are examples of the major impact C. difficile can have on health care 
systems [1,9-12]. Through the implementation of standardized surveillance case definitions, a consider-
able proportion of cases of CDI occurring outside hospitals has also been identified [1,13-15]. Increased 
awareness of the role of C. difficile as a global health problem is required to reduce morbidity and control 
rates of CDI [16,17]. However, there are limited evidence characterizing its role as a global public health 
problem. We aimed to conduct a comprehensive examination of globally reported rates of CDI incidence, 
in order to develop baseline epidemiological estimates of incidence and identify characteristics and gaps 
in the available evidence base.
METHODS
Identification of eligible publications
We searched seven electronic databases (Medline, Embase, Global Health (through Ovid), CINAHL, LI-
LACS, WHO Library, and Web of Science) in January 2016 to identify publications reporting incidence 
rates of CDI. Search strategies were developed with the assistance of a medical librarian and included a 
combination of MeSH and keywords relevant for CDI and incidence or burden of disease. An internet 
search to identify the most recent data from national surveillance reports was also conducted to supple-
ment evidence from published literature (Table S1 in Online Supplementary Document). Details on 
eligibility criteria for the review are described in Table 1. Two reviewers (EB, TS) screened the records 
obtained through electronic medical databases and identified articles that met the inclusion criteria. We 
included studies and surveillance reports with a publication year between 2005 and 2015 inclusive and 
reporting CDI cases identified through positive laboratory assay or endoscopic findings using surveillance 
case definitions [18] or administratively coded CDI hospitalizations (eg, International Classification of 
Diseases (ICD) ICD-9-ICM = 00845.0 or ICD-10 = A04.7). Studies focusing on recurrence, asymptomatic 
colonization or mortality, or those published in languages other than English or Spanish were excluded. 
We also excluded data from periods of outbreaks or from intervention arms of infection control studies.
Data extraction
Data from the included studies were extracted by at least two reviewers (EB, CL, JB, IL) using an Excel 
form which was piloted before its final use. Uncertainties or discrepancies on data extraction were re-
solved by discussion between extractors. We extracted data on the study setting, duration, and design, 
Table 1. Eligibility criteria
Inclusion criteria
Observational (during non-outbreak periods) or interventional studies (pre-intervention period) and national surveillance reports published between 
2005 and 2015.
English and Spanish language (for peer-reviewed publications).
Publication reports rates of CDI incidence for individuals of all ages in any of the following settings: hospitals, medical intensive care units, internal 
medicine wards, long term care facilities or nursing homes and in the community.
Case ascertainment methods and case definition compatible with current CDI surveillance (laboratory or histological-diagnosis) or administrative 
coded hospitalizations (ICD9-9-CM:008.45; ICD-10:A04.7) are clearly reported.
Data on incidence of CDI rate can be extracted as an independent outcome and at least two of the following are available: number of cases during 
study period, study population (denominator) or rate.
Exclusion criteria:
Articles published before 2005 or reporting data for a study population already considered in the review.
Methods for case ascertainment are not clearly reported.
Interventional before-and-after studies without clear background rate or studies reporting rates outbreak periods exclusively.
C. difficile assessed as a co-infection, composite outcome (eg, set of health care-associated infections), or defined as an adverse drug reaction or anti-
biotic associated diarrhoea without C. difficile laboratory/code confirmation.
Study population at risk from which cases were identified narrowed by a prior selection process (eg, only diarrheal patients, those on antibiotics, 
co-morbidity-specific groups).
Case-reports, systematic reviews, narrative reviews, letters to editors, brief communications, commentary pieces.
Global burden of C. difficile infections
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case ascertainment methods, and case definition details. Data were extracted in accordance to the fol-
lowing settings of CDI acquisition: health care facility-associated (HCF), hospital onset health care facili-
ty-associated (HO-HCF), community-associated (CA), any setting /unspecified CDI and for three selected 
high-risk settings: medical or general intensive care units (ICU), internal medicine wards (IM), and long-
term care facilities (LTCF), including nursing homes. For ICD-coded hospitalizations, we included pub-
lications reporting the number of hospitalizations with CDI code as a primary and secondary diagnosis. 
or data extraction, incidence rates were collected based on number of CDI cases that adhered to recom-
mended surveillance case definitions, but also included studies with modified case definitions if this was 
clearly reported. Authors of publications eligible for inclusion were contacted to obtain the number of 
cases if additional eligible categories were reported in order to enable inclusion in the meta-analysis. To 
minimize potential bias towards large studies in meta-analyses, data from multicentre publications were 
extracted per health care facility and counted as an individual data point. Studies with data from facilities 
also included in national surveillance or other multicentre publications were excluded to avoid potential 
duplication of the same study population. Depending on the case definition, incidence for the following 
metrics were extracted and standardized: number of CDI cases per admissions (per 1000 admissions per 
year), incidence density (per 10 000 patient-days), and cumulative incidence of CDI cases over the total 
population at risk (per 100 000 population per year).
Statistical analysis
The total number of CDI cases by admissions, total patient-days, or population for each category, rates 
and 95% confidence intervals (CI) were extracted from publications as reported by authors or calculated 
based on available data. The distribution of CDI incidence rates identified was summarized in terms of 
interquartile ranges and median values as follows: for HCF and HO-HCF (including high-risk settings: 
ICU, IM, and LTCF) in terms of incidence density and cases per admissions, and for CA, any or unspec-
ified setting of acquisition, or ICD-coded hospitalization in terms of cases per admissions and cumula-
tive incidence.
Rates of CDI incidence were pooled using the metan command in Stata version 14 (StataCorp, College 
Station, Texas, USA). When a publication reported different rates for the same study population using 
different case ascertainment methods (eg, based on review of patients or laboratory charts vs administra-
tive records) we used the number of CDI cases where patient’s records had been reviewed. A small value 
(0.05) was used as continuity correction to include rates with zero CDI cases in the meta-analysis. Esti-
mates were developed using a random effects model, acknowledging the heterogeneity in observational 
studies conducted in diverse settings.
Where possible, we performed and reported subgroup meta-analyses by location (WHO regions; the 
Americas region was divided into North America and Latin America) and age group (children [≤15 years 
or pediatric hospitals], adults [≥15 years], elderly [≥65 years], and all or unspecified age [≥0-2 years and 
studies without information on age or where children were not explicitly excluded]). Subgroup analyses 
were performed for categories with at least three different data points.
RESULTS
Overview of included studies
A total of 229 publications [2,11,12,19-244], including 14 national surveillance reports, were included 
from over 12 000 publications assessed for eligibility. The literature review process is summarized in the 
PRISMA flowchart in Figure 1. Data extracted from each of the included studies are available in (Tables 
S2-S8 in Online Supplementary Document).
We included data on rates of CDI incidence from 41 countries. The majority of reports (195/229) were 
from Europe and North America. Incidence data eligible for inclusion from other regions: Western Pacif-
ic, Latin America, Eastern Mediterranean, and Africa were identified less frequently, and no reports from 
the South-East Asia region was included. Sub-analyses on CDI rates by world region are reported for Eu-
rope, North America and the Western Pacific regions for categories with suitable number of data points 
to conduct a meta-analysis.
Of the 229 publications included, 89 publications reported rates of HCF-CDI (incidence density and/
or cases per admissions) and 57 publications reported data for HO-HCF CDI (incidence density and/or 
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cases per admissions). Rates of CA-CDI were reported in 39 publications with almost all data from coun-
tries in North America, Europe, and the Western Pacific. CDI in high-risk settings (ICU, IM, and LTCF; 
56 publications) were also for the most part identified from countries in North America, Europe, Lat-
in America and the Western Pacific. CDI rates for children and the elderly were reported in 37 and 33 
publications, respectively. The number of individual data on rates for each of the CDI categories and age 
groups are presented in Table 2.
Regardless of metric, there were large variations in rates of CDI incidence across categories and age groups. 
Figure 2 depicts the median and range of all rates of CDI incidence reported in included studies in the 
review.
Meta-analysis
Table 3 shows the results from the meta-analyses, by CDI categories, regions and age groups.
CDI cases per admission
Incidence of CDI reported in individual studies ranged from 0 to 35.15 cases per 1000 admissions per 
year (Figure 2, panel a). The highest median number of CDI cases per admissions were reported from 
ICU and IM wards; with the highest meta-estimate for incidence rate (IR) of 11.08 (95% CI = 7.19-17.08) 
per 1000 admissions per year for ICU-onset CDI. Among all ages, meta-estimates rates of HO-HCF and 
HCF-CDI were similar (IR = 2.09 (95% CI = 1.16-3.74) per 1000 admissions per year and 2.24 (95% 
CI = 1.66-3.03) per 1000 admissions per year, respectively), and rates for CA-CDI were lower (IR = 0.55 
(95% CI = 0.13-2.37) per 1000 admissions per year) (Table 3).
Estimates in the elderly were similar to those than for adults or higher compared to the other age groups 
(with children having the lowest incidence rates). Although regional level estimates were not strictly com-
parable, North America generally reported higher rates across CDI categories and age groups (Table 3).
CDI incidence density
CDI incidence density reported in individual studies ranged from 0.11 to 50.3 per 10 000 patient-days 
(Figure 2, panel b). The highest estimated incidence density by meta-analysis was in the ICU and IM 
wards, the highest incidence rate 13.74 (95% CI = 9.46-19.93) per 10 000 patient-days was for ICU-on-
set CDI. The meta-analysis estimates for HO-HCF and HCF were similar (IR = 4.14 (95% CI = 3.10-5.53) 
per 10 000 patient-days and 3.54 (95% CI = 3.19-3.92) per 10 000 patient-days, respectively), as was the 
incidence density in LTCF (IR = 4.41 (95% CI = 2.36-8.23) per 10 000 patient-days) (Table 3).
Meta-estimates for the four age categories were calculated for HCF-CDI incidence density, where the high-
est density was observed among the elderly (IR = 10.95 (95% CI = 5.08-23.59) per 10 000 patient-days). 
Incidence density of HO-HCF CDI and HCF-CDI were also higher for adult populations compared to 
that in patients of all ages. Based on the limited data at regional level, we observed that North America 
had the highest CDI incidence density.
Figure 1. PRISMA flowchart.
Global burden of C. difficile infections
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Cumulative incidence of CDI
Cumulative incidence of CDI reported in in-
dividual studies ranged from 1.12 to 631.80 
per 100 000 population per year (Figure 2, 
panel c). The majority of data for cumulative 
incidence of CDI hospitalizations were avail-
able from large databases in the United States. 
Based on data from ICD- coded hospitaliza-
tions, the estimate of cumulative incidence 
rate for all ages is 49.36 (95% CI = 34.01-
71.75) per 100 000 population per year. This 
estimate is similar to the rate based on CDI 
cases identified through positive laboratory 
assay and clinical criteria (IR = 41.94 (95% 
CI = 30.30-58.05) per 100 000 population 
per year) (Table 3). For the latter, estimates 
from individual studies ranged from 13.42 per 
100 000 population per year in a study con-
ducted in Spain in 2003 where national labo-
ratories were surveyed to 147.20 per 100 000 
population per year in a study with sentinel 
surveillance in the United States where rates 
were adjusted for use of molecular laborato-
ry assays. At the national level, increases in 
CDI hospitalization rates per 100 000 popu-
lation were reported, for instance, in Finland 
(from 16.0 in 1996 to 34.0 in 2004) [12], in 
Belgium (from 16.5 in 1999 to 44.3 in 2008), 
and in the United States (from 48.8 in 1999 
to 114.6 in 2008) [11].
Where meta-analysis by age groups was pos-
sible, the results for the cumulative incidence 
for the elderly was higher compared with 
the other age groups; for any CDI (regard-
less of setting of acquisition), the overall es-
timate from meta-analysis was 323.32 (95% 
CI = 217.82-479.91) per 100 000 population 
per year. Europe had the highest estimates of 
cumulative incidence rate CA-CDI in all age 
groups, though confidence intervals overlap 
with the estimate for North America.
DISCUSSION
The aim of this study was to examine reports 
of CDI incidence rates in order to develop 
an overall estimate and to identify gaps in 
the current evidence base globally. We found 
variations of CDI occurrence in terms of rates, 
within categories as well as between world re-
gions. From our meta-analyses, the estimated 
overall incidence rate of HCF-CDI for patients of all ages was 2.24 per 1000 admissions per year and 
3.54 per 10 000 patient-days.
The implementation of robust surveillance systems is important to ascertain the burden of CDI across 
and to help identify any future changes in rates [2,14]. Through our review of the literature, we found 
that the highest rates of CDI for the majority of categories assessed were reported in North America. It 
Figure 2. Distribution of CDI incidence rates by category and age groupI a) 
number of CDI cases per 1000 admissions per year, b) incidence density 
per 10 000 patient-days, c) cumulative incidence per 100 000 population 
per year. Abbreviations: CDI, Clostridium difficile infection; HO-HCF, hospi-
tal-onset health care facility-associated; ICU, intensive care unit; IM, internal 
medicine; HCF, health care facility-associated; CA, community-associated; 
ICD, international classification of diseases; LTCF, long term care facility.
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is likely that this finding is due to im-
provements in case detection and in-
fluenced by the use of high-sensitivi-
ty testing methods such as nucleic acid 
amplification testing which can lead to 
overestimation of CDI rates [2,149,245]. 
In Europe, our meta-estimate for health 
care-associated CDI density rates (3.14 
[95%CI = 2.80-3.53] per 10 000 pa-
tient-days) is similar to estimates from re-
gional surveys in 2005, 2008 and 2012-
13 [3-5] (for which the overall estimate 
is 4.08 (95%CI = 3.52-4.74) per 10 000 
patient days when data are analyzed by 
meta-analysis, (Appendix S9 in Online 
Supplementary Document). Our me-
ta-estimate is also similar to the medi-
an rate based on aggregate data from 37 
European hospitals in 14 countries in 
2013 (median 3.7 (range: 0.6-18.5) per 
10 000 patients days) [246]. Variations 
in CDI rates may also be due to other 
differences in case ascertainment, both 
regionally and globally, such as practic-
es and criteria for specimen collection, 
testing policies and methodologies, un-
der-ascertainment of cases, and report-
ing requirements [5,246,247]. Efforts 
to harmonize CDI surveillance proto-
cols within and across countries, such 
as in Europe, will facilitate the monitor-
ing of epidemiological changes, imple-
mentation of infection control protocols 
[246,248]. Our review shows there is a 
paucity of data on the incidence of CDI 
from regions other than North Ameri-
ca, Europe and the Western Pacific. This 
gap in the evidence base is noteworthy 
as there is evidence of high burden of 
CDI in other world regions [249]. Lim-
ited country-specific data may be due to 
a combination of lower prevalence and 
C. difficile not being tested commonly in 
these regions [250,251]. Identifying the 
global transmission of C. difficile by mo-
lecular characterization is also an import-
ant component of surveillance [252] that 
will further advance our understanding 
of its associated burden.
Our assessment of rates by age groups 
shows the importance of age-specific 
rates to monitor and address the burden 
of CDI effectively. Our meta-estimates of 
CDI rates provide evidence for the mag-
nitude of the burden among across age 
groups and consistently show that elder-
ly populations are disproportionally af-Ta
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s
fected by CDI; as incidence rates increase with increasing 
age [11] and over 80% of CDI deaths occur in those over 
65 years [2]. The high burden of C. difficile on older adults 
may be due to a range of factors including: more frequent 
interactions with health care systems, higher use of an-
timicrobials, and physiologic changes such as decreases 
in immune responses and multi-morbidity [2]. Some risk 
factors for CDI in the elderly are modifiable, through ac-
tions such as antimicrobial stewardship [253] and the tar-
geting of severe and recurrent cases of CDI, which may 
impact morbidity and outcomes [254]. These approach-
es are also relevant to cases of CDI in other age groups. 
Though we found low rates of CDI among the paediatric 
population, we also identified discrepancies in the inclu-
sion criteria for classifying pediatric CDI cases. There is a 
high carriage rate of C. difficile in neonates. Consequently, 
C. difficile is often thought to be non-pathogenic in infants 
and assessing the burden of CDI in this population is more 
difficult [255]. Further, episodes of disease are often of 
shorter duration and fewer complications as compared to 
adults [256]. Considering that increases in the rate of CDI 
hospitalizations in children have been reported, in North 
America for instance [244,257,258], and the limited infor-
mation regarding the burden of CDI, careful assessment of 
surveillance data among the pediatric population is war-
ranted. It is important that studies adhere to standardized 
surveillance recommendations (eg, infants should be ex-
cluded both from the number of cases and the study pop-
ulation in incidence rate calculations) and that CDI rates 
are analyzed for key age groups to identify monitor sub-
groups at risk of disease.
While there is evidence from individual studies that the 
incidence of CDI in ICU patients is decreasing [37,112], 
our study showed CDI rates were consistently high in 
the ICU or IM setting. These high rates may be related 
to the multiple major risk factors that are often found in 
critically ill or older hospitalized patients [259]. CDI in 
the ICU has been associated with an increase in mortal-
ity, and increased length of stay compared to other set-
tings [259,260] highlighting the importance for develop-
ing strategies and protocols for reducing infection in these 
settings. Our review also indicates the need for assessments 
of CDI in nursing homes and other LTCF, where limited 
data are available currently and the burden is estimated to 
be high [222,261,262].
The rates of CA-CDI identified through this analysis were 
generally low, yet, comparable across world regions. Un-
der-ascertainment or under-reporting of CA-CDI may have 
contributed to the lower rates identified, as well as the 
lower density of individuals in the community who are at 
high-risk for CDI. In countries where research has been 
conducted, such as in the US and the UK, a substantial 
proportion of CDI cases that are acquired and have symp-
tom onset in the community (20%-45% of all CDI are 
CA-CDI [1,2,75,263]). Understanding the burden of CA-
CDI is important as these cases may be characterized by 
different risk factors, with a younger age group, present-Ta
bl
e 
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ti
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ing with less severe disease, and with less prior exposure to antimicrobials [121]. Further knowledge of 
these factors and on the links with health care setting is important to develop strategies for lowering the 
rate of CDI in these distinct populations.
To our knowledge, this is the largest meta-analysis of CDI incidence data to date obtained data using 
publications from a 10-year period to identify a substantial amount of data. This comprehensive review 
allowed us to estimate CDI rates for a range of metrics across settings. Through the exclusion of studies 
that reported rates from outbreaks, our estimates provide a baseline epidemiological rate of the burden 
associated with CDI. However, there are limitations to our review and meta-analysis. One limitation is the 
low number of reports from several countries, preventing a truly global picture of CDI rates. Though this 
could partially be influenced by our inclusion criteria (peer-reviewed articles in English and Spanish), we 
added to the global reach of our search by including data from publically available surveillance reports. 
Other sources of data, beyond the scope of our study, including short bulletins and publications in other 
languages need to be systematically assessed. We also identified a limited number of reports of CDI for 
some clinical settings and case definitions (such as LTCF and community), which limits the estimation of 
the impact of C. difficile on these diverse populations. We used data in studies published between 2005 
and 2015 to include a wide range of relevant reports. However, rates in the early years of these publi-
cations (ranging from 1993 until 2015) may be less representative of the current epidemiology of CDI 
due to changes in rates over time. In addition, some recent data on CDI incidence from 2015 may have 
not been included in our estimates because our search criteria might not have captured studies during 
this year. Finally, results from meta-analyses are impacted by the characteristics of the primary studies, 
which may include variations in case definitions, testing methods, and case identification. We aimed to 
limit these variations in this study through our inclusion criteria and analysis, yet, heterogeneity remains.
CONCLUSIONS
This study provides baseline epidemiological CDI rates and uncertainty ranges for a variety of settings 
highlighting the high global burden of disease associated with C. difficile. Our results also emphasize the 
need for the application of standardized surveillance recommendations, the reporting of age-specific in-
cidence rates, and research in countries were sustainable surveillance by national or regional authorities 
is not possible to obtain a fuller picture of the burden of CDI. Improving surveillance and case ascertain-
ment rates globally is important to characterize, to understand the burden of disease associated with C. 
difficile, and to implement effective prevention and infection control measures.
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